DSIP
Small, mixed human sleep studies; no established dose.
Named in the 1970s for the deep sleep it seemed to cause in rabbits. The name has outlasted the evidence. Also called Delta sleep-inducing peptide and Emideltide.
What the evidence shows
Side effects and risks
Who should avoid it: With so little evidence of benefit, there is little reason to accept unknown risks.
How it works
- Where it acts
- No receptor has been found.
- What it changes
- Early rabbit studies suggested more deep sleep. Later studies did not hold up consistently.
- What people notice
- Human sleep studies are small and mixed.
How it has been given in studies
Into a vein in the afternoon, before nights in a sleep laboratory. There is no established dose for the injections and sprays sold online.
Getting it in the United States
The legal route for DSIP
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Research-use-only online sellers
With compounding closed, users turn to online grey-market products sold as research chemicals. Independent tests of such peptides have found bacterial contamination, heavy metals and under-dosing.
Source: AJMC, 2026-08
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Compounding pharmacy
FDA restricted compounding of emideltide from 2023 and the 2026 advisory panel voted against lifting that. Pharmacies cannot lawfully compound it under current policy.
Source: AJMC, 2026-07
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Some fall asleep faster
Reported problems
- Nothing
- Headache, odd dreams
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Benefit reportedcase report - 1 person - 1984
A 1984 Swiss paper describes one patient with insomnia linked to organic brain disease who responded well to DSIP. No controlled follow-up is described in the abstract.
Source: European Neurology, 1984
What experts and influencers say
Paraphrased from the linked sources.
Before the panel that reviewed emideltide and six other peptides, said a reputable advisory panel would normally exclude members with a financial stake in the outcome.
Peter LurieWebsiteWarns against
Photo source: aspenideas.org
Lists emideltide, the drug name for DSIP, among compounding substances with possible safety risks. Cites possible immune reactions, hard-to-characterize impurities and no identified safety data for the proposed route.
US Food and Drug AdministrationSourceWarns against
Voted 7-6 with one abstention against adding emideltide to the compounding list. It was the only one of seven peptides the panel rejected. Uses reviewed were opioid withdrawal, chronic insomnia and narcolepsy.
FDA Pharmacy Compounding Advisory CommitteeSourceWarns against
Money: Press reports say at least seven members of the rebuilt panel have ties to peptide businesses or clinics
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
Summarized his clinic's early studies and reported that DSIP given before sleep improved sleep in insomnia patients, with sleep structure normalizing after repeated administration.
Source: European Neurology, 1984
Dietrich Schneider-HelmertSourceRecommends
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
FDA advisers vote to ease peptide restrictions, despite agency concerns
Will Stone, NPR
Reports a panel backing most gray-market peptides while voting down emideltide, the drug name for DSIP, which is sometimes used for insomnia.
Shows DSIP (emideltide) was the one peptide rejected.
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Lizzy Lawrence and Sarah Todd, STAT reporters
Covers the panel's narrow 6-7 rejection of emideltide, the drug name for DSIP, with a dissenting member warning of dangerous downstream consequences.
Explains why the panel turned this peptide down.
When options run out
Uses people turn to when standard treatment has failed.
Chronic insomnia after standard treatment fails
- Who
- People with long-standing insomnia who find sleeping pills ineffective or intolerable.
- Evidence
- Small 1980s European studies reported better sleep. FDA staff in 2026 found too little evidence of effectiveness and an advisory panel voted against compounding.
Opioid withdrawal and narcolepsy
- Who
- People in opioid withdrawal or with narcolepsy seeking non-standard options.
- Evidence
- These uses were put to the FDA panel in 2026. FDA staff said evidence of effectiveness was insufficient and the panel declined to back compounding.
Source: Bloomberg Government, 2026-07
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does DSIP help you sleep?
The one double-blind study this book could read, in 16 people with chronic insomnia, found small changes on sleep-lab measures and none in how people felt they slept. Its authors judged it unlikely to be of major benefit.
How does DSIP work?
No receptor has been found. Early rabbit studies suggested more deep sleep, but later studies did not hold up consistently.
Is DSIP safe?
FDA has found no safety information for it and cites the risk of immune reactions and impurities. With so little evidence of benefit, there is little reason to accept unknown risks.
Can DSIP be compounded in the US?
FDA advisers voted 6 to 7 against compounding in July 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Bes et al. 1992: DSIP in chronic insomnia
- McDermott: July 2026 advisory committee votes
- FDA: bulk substances that may present significant safety risks
Structure: PubChem